Financial StabilityBiohaven announced an up to $600 million non-dilutive capital agreement with Oberland Capital, which extends runway and alleviates financing risk.
Regulatory InspectionsThe company completed the mid-cycle review meeting with the FDA for troriluzole in SCA, and it indicated that the regulatory inspections of the company and key clinical research sites are completed with timelines reaffirmed.
Regulatory ProgressThe NDA resubmission for troriluzole was accepted under priority review.